Gilead’s $7.8B Arcellx Deal Marks Strategic Shift in CAR T-Cell Therapy Race

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2026-04-28 18:16:03

BTCCSquare news:

Gilead Sciences (GILD) completed its $7.8 billion acquisition of Arcellx on April 28, gaining full control of anito-cel, a promising CAR T-cell therapy for multiple myeloma. The deal retests an 11-year technical base at $123.47, with analysts projecting 35% upside to $173 by year-end.

The stock now trades near $128 — down 8% this month but up 22% YoY — with RSI hitting 27, its most oversold level in a year. Nearby 200-day SMA support suggests potential stabilization.

While the acquisition will reduce 2026 EPS by $5.57-$5.67, Gilead eliminates future profit-sharing obligations and gains full commercialization control. The strategic move positions the company to accelerate development ahead of potential FDA approval.

By:

Log in to Reply

SanDisk and Western Digital Receive AI-Driven Price Target Upgrades Amid Tight Chip Supply

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.